![](https://www.federaltimes.com/resizer/IuKAhEJB1PpawBKwQXCFJvC9i-o=/400x0/filters:format(jpg):quality(70)/cloudfront-us-east-1.images.arcpublishing.com/archetype/OLNHPCRIENFIBONVOUB5UC2MXU.jpg)
Latest ""
![](https://www.federaltimes.com/resizer/IuKAhEJB1PpawBKwQXCFJvC9i-o=/400x0/filters:format(jpg):quality(70)/cloudfront-us-east-1.images.arcpublishing.com/archetype/OLNHPCRIENFIBONVOUB5UC2MXU.jpg)
![](https://www.federaltimes.com/resizer/nORYAeEnOrpsrLuZzHmdZDRkDqg=/400x0/filters:format(jpg):quality(70)/cloudfront-us-east-1.images.arcpublishing.com/archetype/KVQTO2U7XNDMNFHTEGVDOEZXCI.jpg)
Drug agency is holdout in Biden push to loosen federal marijuana rules
Federal law still delegates the authority to classify drugs to the DEA administrator.
DEA’s No. 2 quits amid reports of consulting work for Big Pharma
Louis Milione’s consulting for Big Pharma preceded his 2021 return to the DEA, renewing concerns about the revolving door between government and industry.
DEA failure to punish opioid distributor fuels revolving door question
The delay raised concerns about how the revolving door between government and industry may be impacting the DEA’s mission to police drug companies.
By Joshua Goodman
Senator demands DEA boss explain no-bid contracts, hires
Milgram’s boosters inside and outside the agency have defended her actions as part of an ongoing effort to clean house.
By Josh Goodman
DEA chief faces probe into ‘swampy’ hires, no-bid contracts
Among the spending under scrutiny is $4.7 million for “strategic planning and communication” and other contracts used to hire people Milgram knew.
By Josh Goodman